Device Trial Radar · NCT07404657
Preliminary Assessment of an Automated Tool for Diabetic Retinopathy Screening
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
198
Actual
Start
Feb 6, 2026
Primary completion
Jun 17, 2026
Study completion Jun 17, 2026
Sponsor
- Lead sponsor
- Centervue SpANot on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 11, 2026
Design
- Study type
- Observational
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to evaluate the performance of a software that uses artificial intelligence to analyze photographs of the retina to help detect diabetic retinopathy. The study will also assess the safety of the software in combination with a fundus camera already available on the market. This software analyzes retinal photographs to detect more than mild diabetic retinopathy in adults with diabetes. The results will be compared to expert human evaluations.
Conditions
- Diabetic Retinopathy (DR)
Interventions
automatic analysis of fundus images performed by the software tool based on artificial intelligenceDevice
the duration of the intervention is the analysis performed by the software tool based on fundus images acquired
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects whose results provided by the automatic AI-based tool match the reading center grading for the identification of referable diabetic eye disease (more than mild DR).Time frame: 1-day visit
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rovia University - Jacksonville (East Coast for Institute Jacksonville)
Jacksonville, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.